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Evaluation of smoking-specific and generic
quality of life measures in current and former
smokers in Germany and the United States
John E. Ware Jr1,2*, Barbara Gandek1,2, Anuradha Kulasekaran3 and Rick Guyer1
Abstract
Background: Health-related quality of life (QOL) surveys include generic measures that enable comparisons across
conditions and measures that focus more specifically on one disease or condition. We evaluated the psychometric
properties of German- and English-language versions of survey scales representing both types of measures in
samples of current and former smokers.
Methods: TQOLIT™v1 integrates new measures of smoking-specific symptoms and QOL impact attributed to
smoking with generic SF-36 Health Survey measures. For purposes of evaluation, cross-sectional data were analyzed
for two independent samples. Disease-free (otherwise healthy) adults ages 23–55 used a tablet to complete surveys
in a clinical trial in Germany (125 current and 54 former smokers). Online general population surveys were
completed in the US by otherwise healthy current and former smokers (N = 149 and 110, respectively). Evaluations
included psychometric tests of assumptions underlying scale construction and scoring, score distributions, and
reliability. Tests of validity included cross-sectional correlations and analyses of variance based on a conceptual
framework and hypotheses for groups differing in self-reported smoking behavior (current versus former smoker,
cigarettes per day (CPD)) and severity of smoking symptoms in both samples and, in the German trial only, clinical
parameters of biomarkers of exposure.
Results: Tests of scaling assumptions and internal consistency reliability (alpha = 0.71–0.79) of the smoking-specific
measures were satisfactory, although ceiling effects attenuated correlations for former smokers in both samples.
Correlational evidence supporting validity of smoking-specific symptom and impact measures included their substantial
inter-correlation and higher correlations (than generic measures) with smoking behavior (favoring former over current
groups) and CPD in both samples. In the German trial, both smoking-specific measures correlated significantly (p < 0.05)
with all four biomarkers. QOL impact attributed to smoking correlated with the SF-36 mental but not physical summary
measures in both samples.
Conclusions: German- and English-language TQOLITv1 surveys have comparable and satisfactory psychometric
properties. Cross-sectional tests, including correlations with four biomarkers, support the validity of the new
smoking-specific measures for use in studies of otherwise healthy smokers. Smoking-specific measures
consistently performed better than generic QOL measures in all tests of validity.
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Background
The past fifteen years have seen increased interest in the
science of assessing tobacco harm reduction [1], particu-
larly more recently for modified risk tobacco products
(MRTPs) [2, 3]. In the United States, enactment of the
Family Smoking Prevention and Tobacco Control Act in
2009 gave the Food and Drug Administration (FDA)
authority to regulate tobacco products. While the FDA has
issued draft guidance on the types of studies recom-
mended to evaluate MRTPs [3], it has acknowledged the
difficulties inherent in making premarket assessments of
the effect that the introduction of a MRTP would have on
the population. The FDA has encouraged development of
innovative analytical methods to estimate the potential
effects of MRTPs [3].
Health-related quality of life (QOL) measures have
been the subject of recent FDA guidelines [4] and have
been used for decades to evaluate the health status of
smokers. Review of studies published over the past two
decades confirmed the widespread use of the Medical
Outcomes Study short-form measures (SF-36 and
others) in cross-sectional and longitudinal studies of
smoking behavior and identified some clear trends link-
ing differences in smoking behavior to QOL [5, 6]. First,
otherwise healthy smokers (who do not have smoking-
related or other chronic conditions) typically scored
above average in relation to the general population but
scored worse than otherwise healthy former smokers.
Second, differences between smoking groups were more
apparent in measures of mental (emotional) health and
general health perceptions (confidence in health). Add-
itionally, secondary analysis of two publicly available US
general population data sets [7] and data from a clinical
study that involved healthy smokers switching to reduced-
toxicant prototype cigarettes (RTPs) for a period of 4 weeks
[8] showed that current smokers scored worse than former
smokers for physical and mental health and wellbeing [9].
These results suggest that generic QOL measures also are
likely to be useful in studying MRTPs, but does not address
the question of whether smoking-specific QOL measures
would be even more useful.
Although a number of validated questionnaires are
available to assess QOL and have proven to be useful in
clinical research [6, 10], generic QOL measures (which
allow health conditions and treatments to be compared)
and smoking-specific QOL measures (which may be more
responsive to changes in smoking behavior) have not been
integrated and standardized. Among the surveys used in
smoking research are the: (a) Smoking Cessation Quality
of Life Questionnaire, which measures generic constructs
of particular importance in smoking research and self-
control over smoking cessation [11, 12]; (b) Clinical
COPD Questionnaire, which includes items specific to
breathing problems rather than smoking [13]; and (c)
PROMIS item banks and short forms measuring nicotine
dependence, social motivation to smoke, and various ex-
pectancies of smoking (coping, emotional and sensory,
health, psychosocial) [14]. These surveys do not compre-
hensively measure current symptoms, functional limita-
tions, or other indicators of health-related QOL with
attributions specifically to smoking.
The Tobacco Quality of Life Impact Tool (TQOLIT™v1)
was designed to integrate smoking-specific and generic
measures of QOL outcomes for current and former
smokers, including those in the range of scores likely to be
observed among smokers who do not have smoking-related
or other chronic conditions (referred to hereafter as “other-
wise healthy”). The underlying conceptual framework of
TQOLITv1 includes new self-report measures of smoking-
related symptoms and a new more comprehensive and
standardized approach to measuring the QOL impact at-
tributed specifically to smoking.
This paper presents the first empirical evaluation of
the TQOLITv1 smoking-specific symptom and QOL im-
pact measures and compares results across two inde-
pendent US and German samples matched in terms of
age and health characteristics. This evaluation addresses
the assumptions underlying scale construction, score
distributions and reliability and examines evidence of
validity of the new smoking-specific measures in relation
to a conceptual framework of hypothesized QOL deter-
minants (i.e., smoking behavior and biomarkers of ex-
posure) as well as differences in generic QOL outcomes
that have been observed in comparisons of groups differ-
ing in smoking.
Methods
Samples
The German sample came from a clinical study compar-
ing reduced toxicant prototype (RTP) and conventional
cigarettes conducted in Hamburg in 2012 and approved
by the independent ethics committee of the Ärztekammer
Hamburg [15, 16]. Data from 125 current smokers (ages
23–55, minimum age is the legal smoking age in Germany
plus 5 years) and 54 former smokers (ages 28–55) who
had both TQOLITv1 and biomarker data were analyzed in
this paper. Smokers had a history of regular smoking for
at least 5 years, typically smoked 10 to 30 cigarettes per
day (CPD) at study entry and could not be on smoking
cessation medication, all as required by the trial protocol
[16]. Former smokers had to have smoked at least 100
cigarettes in their lifetime, regularly smoked 10–30
cigarettes per day for at least 5 years, and quit smoking
for at least 5 years at study entry. Data reported here
were collected at baseline, prior to randomization to
RTP or conventional cigarettes. All respondents were
able to read German and self-administered the survey
through an electronic data capture (EDC) system (CRF
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Health, Helsinki, Finland) on a tablet device with a
one-item-at-a-time interface.
Data for the US matched sample were collected via an
Internet survey administered in December 2011 for the
NIH-sponsored Computerized Adaptive Assessment of
Disease Impact (DICAT) project, which was approved
by the New England Institutional Review Board. Respon-
dents belonged to KnowledgePanel®, a representative
sample of the US adult general population constructed
using address-based sampling [17]. Those who reported
smoking at least 100 cigarettes in their lifetime and who
currently smoked every day or some days were classified
as current smokers in accordance with CDC guidelines
[18]. It should be noted that the US sample included
current smokers reporting as few as one CPD which has
the advantage of increasing variability among lighter
smokers and improving tests of validity. Respondents
who reported smoking at least 100 cigarettes in their
lifetime but did not smoke currently and had quit at
least 5 years ago were classified as former smokers. The
US sample was matched to the German sample by restrict-
ing the age range to 23 through 55 (current smokers) and
28 through 55 (former smokers). All respondents were able
to read English and self-administered the survey through
an EDC system (QOLIX®, John Ware Research Group) with
a one-item-at-a-time interface.
Respondents in Germany who reported clinically relevant
gastrointestinal, renal, hepatic, neurologic, hematologic,
endocrine, oncologic, urologic, pulmonary, immunologic,
psychiatric, or cardiovascular disease, HIV or obesity were
excluded from the clinical trial. Respondents in the US
who reported matching conditions (from a checklist of
35 chronic health conditions) were excluded from the
US sample.
Measures
A conceptual framework or endpoint model is the basis for
developing and evaluating evidence of validity for self-
report measures of health outcomes [4]. The smoking-
specific framework underlying hypotheses about results
from tests of validity identifies relationships between vari-
ables (measures), along a continuum ranging from self-
reported smoking behavior to the most generic health and
well-being outcomes (Fig. 1). Applied to the current study
of smoking behavior and QOL outcomes, this framework
makes an important distinction between tests in relation to
objectively-measured clinical parameters such as bio-
markers of smoking exposure (box 1) and the hypothesized
sequence of self-reported outcomes including smoking-
specific symptoms (box 2) and the QOL impact attributed
specifically to smoking (box 3). Among the hypothesized
advantages of smoking-specific attributions for outcomes is
greater validity than measures with attributions to health in
general (box 4), in relation to both the amount and effects
of smoking. An advantage of generic outcome measures is
their usefulness in comparing outcomes across diseases and
treatment interventions [6, 19]. We report here the first
studies of whether QOL measures with attributions to
smoking, as opposed to health in general, perform differ-
ently in tests of empirical validity.
The Smoking Symptoms scale was compiled by the
investigators on the basis of their experience and their
knowledge of the symptoms of smoking as described in
the literature. It includes eight items asking about preva-
lent smoking-related symptoms (in order of administra-
tion): bad breath, yellowing of teeth, cold hands and feet,
loss of taste and smell, nicotine stained fingers, smoker’s
cough, a hoarse voice, and smell of smoke in hair and
clothes. Items used a 5-choice categorical rating scale
ranging from none of the time–all of the time and did
not have any specific recall period. They have been
extensively evaluated among current and former
smokers in the US general population [9].
The Smoking Impact scale is a smoking-specific ver-
sion of the QOL Disease Impact Scale (QDIS®) [9, 20],
which was developed to fill the conceptual gap between
disease-specific measures that do not measure quality of
life and QOL measures that are not disease-specific.
QDIS is the first measure to standardize the content and
scoring of QOL impact attributed across specific diseases
and conditions (e.g., asthma, obesity, smoking) [21]. The
49-item bank from which all QDIS forms have been
constructed has been extensively evaluated using clas-
sical and modern psychometric methods, with results
Fig. 1 Conceptual framework for smoking-specific and generic endpoints
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justifying standardization of content and scoring of an
overall QOL impact scale across diseases and enabling
the first norm-based scoring of disease–and condition-
specific QOL impact across conditions [9]. The Smoking
Impact scale administered to the German and US sam-
ples was a 7-item QDIS short-form that asked about the
QOL impact of smoking on seven QOL-related content
areas (in order of administration): overall quality of life,
health outlook, physical functioning, fatigue, role and
social functioning, and mental health (Table 1). For
example, one item asked: “During the past 4 weeks, how
often did your smoking limit your physical activities such
as walking or climbing stairs?” with a 5-choice categorical
“Never” to “Very Often” rating scale. The data reported
here enabled formal tests of whether shifting items from
the generic “health” attributions used in the SF-36® Health
Survey to smoking-specific attributions in QDIS increased
the validity of QOL impact scores in relation to other
measures of smoking exposure and impact.
Generic outcomes were measured using the Physical
(PCS) and Mental (MCS) Component Summary measures
from the SF-36v2® Health Survey [7, 22]. These measures
have been used in many studies of smoking [5] and have
been shown to capture clinically-efficacious treatment ef-
fects in the great majority of well-controlled pharmaceutical
trials across more than a dozen therapeutic areas [6].
The Smoking Symptoms and Smoking Impact scales
were scored using the method of summated ratings and
then were converted to norm-based scores using a linear
T-score transformation to have a mean of 50 and standard
deviation of 10 in the US population of ever smokers in
2011 [9]. Higher scores indicate greater frequency of
symptoms and more severe quality of life impact attributed
to smoking (Table 1). SF-36 summary measures were
scored as recommended by their developers [22] and were
normed to have means of 50 and SD= 10 in the 2011
general US population [9].
German translations of TQOLITv1 measures (Smoking
Symptoms, Smoking Impact) were developed using stand-
ard methods including forward and backward translation
and qualitative debriefing with lay people [23]. Translations
were conducted by Mapi, Lyon, France. The International
Quality of Life Assessment (IQOLA) Project German trans-
lation of the SF-36v2 was used in Germany [24].
A detailed study protocol and complete list of biomarkers
for the German clinical study is published elsewhere [16],
as are details regarding laboratory methods used to deter-
mine each biomarker and its accuracy [25]. Briefly, for the
analyses reported here, baseline data (before any interven-
tion) for current and former smokers were analyzed. As in
a previous correlational analysis limited to smoking status,
cigarettes per day (CPD) and biomarkers [25], two urinary
Table 1 Descriptions of smoking-specific and generic measures and biomarkers
QOL Measurea Number of
items
Scoring
directionb
Worst possible score Best possible score
Smoking-Specific
Smoking Symptoms 8 − Report of eight symptoms
(listed in text) all of the time.
None of the 8 smoking-specific
symptoms were reported.
Smoking Impact 7 − Extreme limitations in everyday activities
and quality of life attributed to smoking.
No impact on everyday activities or
quality of life attributed to smoking.
SF-36 Generic
Physical Component Summary
(PCS)
35 + Limitations in self-care, physical, social,
and role activities, severe bodily pain,
frequent tiredness, health rated “Poor.”
No physical limitations, pain, disabilities or
decrements in well-being, high energy
level, health rated “Excellent.”
Mental Component Summary
(MCS)
35 + Frequent psychological distress, social
and role disability due to emotional
problems.
Frequent positive affect, absence of
psychological distress and limitations
in usual social/role activities due to
emotional problems.
Biomarker Test Typec Constituent Non-Tobacco Sources
4-aminobiphenyl
(4-ABP)
Urine BoE 4-ABP Hair dyes, fried food
2-cyanoethylmercapturic acid
(CEMA)
Urine BoE Acrylonitrile Workplace
4-aminobiphenyl hemoglobin
adduct (4-ABP-Hb)
Blood BoED 4-ABP Hair dyes, fried food
2-cyanoethylvaline (CEVal) Blood BoED Acrylonitrile Workplace
aNote: all survey items asked about the past 4 weeks except for Smoking Symptoms which asked for current status
bNegative (−) higher score indicates worse symptoms and quality of life; positive (+) indicates better health and quality of life
cBoE = Biomarker of exposure; BoED = Biomarker of effective dose
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biomarkers representing short and long term exposure,
4-aminobiphenyl (4-ABP) and 2-cyanoethylmercapturic
acid, metabolites of 4-ABP and acrylonitrile respectively,
which have been correlated with tobacco smoke exposure,
and their related hemoglobin adducts of 4-aminobiphenyl
and 2-cyanoethylvaline, which can be viewed as biomarkers
of effective dose, were evaluated (Table 1).
Analysis
This study compared the German and US TQOLITv1 in
terms of data quality, tests of assumptions underlying scale
construction and scoring, reliability and evidence of validity
based on a conceptual framework of hypothesized relation-
ships among smoking status and CPD, biomarkers of
exposure, smoking-specific symptoms and QOL impact as
well as generic QOL measures.
Tests of scaling assumptions for the new Smoking Symp-
toms and Smoking Impact scales included evaluation of
item-total correlations corrected for item overlap and
internal consistency reliability estimated with Cronbach’s
coefficient alpha [26]. A minimum value of 0.30 was ac-
cepted for item-total correlations, while a reliability of 0.70
was accepted as a minimum standard for group-level com-
parisons [27]. In addition, descriptive statistics including the
mean, standard deviation (SD) and score distributions (per-
cent scoring at the best possible score or ceiling effect) were
evaluated for new smoking-specific and SF-36 measures.
In the absence of a “gold standard” for measuring
smoking-specific QOL, evidence of validity was gathered
from multiple tests involving the broad framework of
conceptually-related variables with which correlations
would be expected for valid QOL measures, as shown in
the schematic in Fig. 1 and defined in Table 1. On the
strength of prior analyses correlating smoking status
with biomarkers and also linking CPD to biomarkers
[25], these variables were included among the tests of
validity reported here. The first tests compared all mea-
sures by estimating their point-biserial correlations with
smoking status (0 = former, 1 = current smoker), which is
statistically equivalent to comparing group means for
current and former smokers. Directional hypotheses
tested included positive associations between smoking
behavior (i.e., current status, CPD) and each of four bio-
markers of exposure (Fig. 1, Box 1), Smoking Symptoms
(Box 2) and Smoking Impact (Box 3); and negative asso-
ciations between smoking and generic SF-36 measures
of physical and mental impact. Further, we hypothesized
that smoking behavior and the four biomarkers studied
would be more strongly correlated with Smoking
Symptoms and Smoking Impact measures in comparison
with generic SF-36 measures. Correlations associated
with chance probabilities of p <0.05 were considered
significant.
For tests of the new smoking-specific and generic
measures, current smokers were also divided into three
groups differing in smoking-specific symptom severity:
(1) None (total symptom score averaging less than “A
little of the time”); (2) A little (total score averaging at
least “A little of the time” but below “Some of the time”);
and (3) Some (total score averaging “Some of the time”
or higher). Group means were compared using one-way
analysis of variance (ANOVA). The performance of the
Smoking Impact and generic SF-36 scales was compared
using relative validity (RV) coefficients (F-statistic for
each comparator divided by the F-statistic for the most
valid scale within a test). RV estimates were compared
with consideration of confidence intervals estimated
using empirical bootstrap [28]. As stated above, the hy-
pothesis tested was that the smoking-specific measures
would discriminate better across symptom severity
groups, in comparison with the generic SF-36 measures.
Analyses were conducted in SPSS Version 19 [29] and
Stata 11 [30].
Results
The US sample of 259 ever (current and former)
smokers had the same age range (23–55) as the German
sample of 179 ever smokers by design and did not differ
significantly in mean age (p > .05) (Table 2). A higher
proportion of the US sample were male (55.2 % versus
48.6 %, respectively), although this difference was not
significant at a p < .05 level. Within both samples, current
smokers were younger than former smokers (p < .05),
reflecting the different minimum ages (23 versus 28) in the
smoking groups. The US sample had a higher percent-
age with some post high school education (60.6 % vs
49.2 %, p < .05). In the US population sample, current
smokers also were less educated than former smokers
(p < .05). Gender and race did not differ between
current and former smokers in either sample (p > .05).
Item-total correlations for the Smoking Symptoms and
Smoking Impact scales were substantial (r > 0.40) with
few exceptions, as required for summated rating scales.
Median correlations were slightly higher in the US sam-
ple than the German sample (0.49 and 0.58 vs 0.42 and
0.44 for Smoking Symptoms and Smoking Impact, re-
spectively) (Table 3). As expected for more heteroge-
neous symptoms, item-total correlations for the
Smoking Symptoms scale were lower than for the Smok-
ing Impact scale. The lowest item-total correlation (0.12)
was observed for the first symptom item (bad breath) in
the German sample; however all others exceeded 0.30
which is satisfactory for corrected item-total correlations
in a newly developed scale. While scale internal-
consistency reliability was somewhat higher in the US
sample, it exceeded the recommended standard of 0.70
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for group comparisons for both measures in both
samples.
Means for Smoking Symptoms and Smoking Impact
measures shown to be worse for current than for former
smokers in both German and US samples are docu-
mented along with other results in Table 4. For the
Smoking Symptoms measure, percentages with the best
possible scores (ceiling) were very low for both the US
and German current smokers (4.0 % and 0.0 %) but were
slightly higher for former smokers (10.9 % and 5.6 %).
Similarly, the percent scoring at the ceiling for Smoking
Impact was substantially lower for US and German
current smokers (26.8 % and 40.8 %) in comparison with
former smokers (92.7 % and 94.4 %). The skewness of the
Smoking Impact measure, particularly in the German trial
where 40.8 % of current smokers had the best possible
score, may have constrained the correlational tests reported
in Table 5. In contrast, there were no noteworthy ceiling ef-
fects (% with best possible score) for either generic measure
in either sample.
For comparison purposes, correlation estimates be-
tween smoking status (current = 1, former = 0) are
presented in the first data column of Table 5. In further
support of the conceptual framework underlying the
correlational tests of validity possible in the German
trial sample, significant (p < 0.05) correlations in the
hypothesized direction were observed for CPD and all
four biomarkers in relation to both smoking-specific
measures (Table 5). Correlations with biomarker data
were consistently higher for Smoking Symptoms
(0.38–0.54) in comparison with Smoking Impact
(0.17–0.22). In contrast, the generic physical and men-
tal SF-36 measures did not correlate significantly with
smoking status, CPD or any of the four biomarkers of
exposure in the German sample. This pattern of results
was replicated for the correlation of smoking-specific
measures in relation to CPD in the US sample (r = 0.36–
0.53, p < .01) (Table 5). (By design, biomarkers were not
available for US sample respondents). Three of the four
correlations with smoking status and CPD were significant
(p < 0.05) for the generic physical and mental SF-36 mea-
sures in the US sample, but the magnitude of the correla-
tions was much lower for the generic measures than the
smoking-specific measures (Table 5). Smoking Symptoms
and Smoking Impact scales were moderately (0.37–
0.55, p < .01) inter-correlated, as hypothesized, in both
samples. Correlations between smoking-specific and
generic measures were higher and significant for the
mental (MCS) measure (−0.15 to −0.42, p < .05) in
comparison with the physical (PCS) (−0.09 to −0.16, 3
of 4 NS) measure.
Finally, evidence from tests of discrimination across
groups differing in the frequency of smoking symptoms
supported the hypothesized greater discriminant validity
of the Smoking Impact scale over the two generic mea-
sures, in both samples (Table 6). Relative validity was
consistently greatest for Smoking Impact (RV = 1.0) in
Table 3 Psychometric properties of smoking-specific measures,
German and US current and former smokers
Item-Total correlations Reliabilitya
Median Range
German Sample (N = 179)
Smoking Symptoms 0.42 0.12–0.58 0.71
Smoking Impact 0.44 0.33–0.62 0.72
US Sample (N = 259)
Smoking Symptoms 0.49 0.37–0.62 0.76
Smoking Impact 0.58 0.48–0.72 0.79
aInternal consistency reliability computed using Cronbach’s alpha
Table 2 Demographic characteristics of German and US samples
German sample US sample
Current smokers
(N = 125)
Former smokers
(N = 54)
Ever smokers
(N = 179)
Current smokers
(N = 149)
Former smokers
(N = 110)
Ever smokers
(N = 259)
Mean age (SD) 39.0 (9.2) 43.1 (7.8) 40.2 (8.9) 40.2 (9.8) 43.6 (8.2) 41.6 (9.3)
Range 23–55 29–55 23–55 23–55 28–55 23–55
Male (%) 48.8 48.2 48.6 55.0 55.5 55.2
Race (%)
White 88.8 92.6 89.9 85.7 88.2 86.8
Black 0.0 0.0 0.0 7.5 6.4 7.0
Other 11.2 7.4 10.1 6.8 5.4 6.2
Education (%)a
Up to high school graduate 53.6 44.4 50.8 46.3 30.0 39.4
Some post high school 24.0 22.2 23.5 37.6 27.3 33.2
College graduate or professional training 22.4 33.4 25.7 16.1 42.7 27.4
aGerman and US Ever Smoker groups differed (p < 0.05)
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both samples in comparison with the two generic mea-
sures (RV = 0.06–0.35).
Discussion
Overall, study results indicate that the new smoking-
specific TQOLITv1 scales are likely to be useful in filling
what would otherwise be conceptual and measurement
gaps between smoking behaviors and symptoms and gen-
eric QOL outcomes. The Smoking Impact score estimated
from responses to standardized questions differing primar-
ily from SF-36 in terms of specific attribution to smoking
was consistently more valid than the generic SF-36, in both
German and US samples. Thus, along with Smoking
Symptoms, the new Smoking Impact scale may advance
understanding of how differences in smoking behavior and
resulting differences in exposure might lead to differences
in generic QOL outcomes. It is encouraging that the
pattern of results from tests of psychometric properties and
evidence from empirical tests of validity that could be
performed for both samples was largely comparable.
Conceptual and methodological issues and noteworthy
limitations of the study are discussed below.
Evaluation of the conceptual framework guided by the
endpoint model (Fig. 1) yielded broad evidence supporting
Table 4 Means and ceiling effects of measures by smoking group and country
German sample US sample
Current smokers
(N = 125)
Former smokers
(N = 54)
Ever smokers
(N = 179)
Current smokers
(N = 149)
Former smokers
(N = 110)
Ever smokers
(N = 259)
Measurea Mean (SD) % Best Mean (SD) % Best Mean (SD) % Best Mean (SD) % Best Mean (SD) % Best Mean (SD) % Best
Smoking-Specific
Symptoms (−) 58.2 (8.6) 0.0 48.8 (6.6) 5.6 55.4 (9.1) 1.7 55.1(10.4) 4.0 45.3(5.4) 10.9 50.9 (9.9) 6.9
Impact (−) 50.3 (6.4) 40.8 45.6 (3.0) 94.4 48.9 (6.0) 57.0 54.0 (9.8) 26.8 45.8 (3.3) 92.7 50.5 (8.8) 54.8
SF-36 Generic
PCS (+) 57.1 (4.3) – 56.5 (4.2) – 56.9 (4.3) – 52.5 (7.6) – 55.0 (7.1) – 53.6 (7.5) –
MCS (+) 54.6 (5.6) – 53.3 (5.8) – 54.2 (5.7) – 47.9 (11.6) – 50.0 (9.8) – 48.8 (10.9) –
aNegative (−) higher score indicates worse symptoms and quality of life; positive (+) indicates better health and quality of life
Table 5 Correlations among measures, German and US current and former smokers
Sample and measure Scoringa Current smoking statusb CPD Smoking-specific symptoms Smoking impact PCS MCS
German Sample (N = 179)
Biomarkers
4-ABP 0.720** 0.817** 0.439** 0.171* 0.013 0.099
CEMA 0.681** 0.773** 0.375** 0.179* −0.006 0.064
4-ABP-Hb 0.712** 0.826** 0.538** 0.189* −0.062 0.137
CEVal 0.659** 0.793** 0.500** 0.221** −0.054 −0.046
Survey Measures
Smoking Symptoms − 0.476** 0.537**
Smoking Impact − 0.354** 0.251** 0.372**
SF-36 PCS + 0.060 0.005 −0.091 −0.099
SF-36 MCS + 0.104 0.107 −0.154* −0.298** −0.041
US Sample (N=259)
Survey Measures
Smoking Symptoms − 0.491** 0.527**
Smoking Impact − 0.465** 0.364** 0.550**
SF-36 PCS + −0.163** −0.207** −0.162** −0.097
SF-36 MCS + −0.098 −0.154* −0.418** −0.371** -0.068
*p < .05, **p < .01
aNegative (−) indicates higher score equals worse health; positive (+) indicates higher score equals better health
b1 = current smoker; 0 = former smoker
Note: 4-ABP = 4-aminobiphenyl; CEMA = 2-cyanoethylmercapturic acid; 4-ABP-Hb = 4-aminobiphenyl hemoglobin adduct; CEVal = 2-cyanoethylvaline hemoglobin
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the validity of the new Smoking Symptoms and Smoking
Impact measures in relation to each other as well as hypoth-
esized antecedents including smoking status, CPD among
smokers, and objective biomarkers of exposure. The new
scales were also correlated with SF-36 physical and mental
measures of hypothesized generic outcomes. It is a note-
worthy limitation that the evidence of validity not based on
self-report was available for only the German sample. How-
ever, this is the first study that we are aware of linking inde-
pendent laboratory measures of biomarkers of smoking
exposure to QOL survey measures. Correlations for both
Smoking Symptoms and Smoking Impact were significant
with all four biomarkers in the hypothesized direction (r =
0.17–0.54) and three of eight were substantial in magnitude.
The latter results supporting the validity of smoking-specific
measures are in contrast to the insignificant correlations be-
tween the two generic SF-36 measures and CPD and all four
biomarkers (r = 0.01–0.14, median = .05, p > 0.05) in the
German trial. In contrast to the German trial, both generic
measures correlated significantly with CPD in the US sam-
ple. Because very light current smokers (1–9 CPD) excluded
from the German trial were included in the US sample,
differences in CPD variability may be a factor underlying
differences in results.
Analyses of differences in smoking behavior and
smoking-specific symptoms reported here and changes
in smoking behavior reported in other studies [31]
suggest that there may be concurrent QOL benefits from
reduced smoking exposure. In the current relatively
healthy samples, the QOL benefits associated with re-
duced smoking exposure were particularly mental health
benefits, confirming results from some previous studies
[32]. Although US study participants were intentionally
matched with those in the German trial in terms of age
and absence of most chronic conditions, important
differences in participant characteristics remained. The
German sample was lower in educational level and in-
cluded a higher proportion of female smokers in compari-
son with the US general population. These factors should
be considered in generalizing study findings and could have
contributed to differences in results across samples.
Translation of one of the symptom items (“bad breath”)
should be evaluated further in light of the low item-total
correlation for the German translation. Is this a problem of
translation or cultural adaption or simply due to the hetero-
geneity of smoking symptoms? This important issue should
be addressed using qualitative methods, which can also be
applied to new items measuring smoking impact. The con-
tent of the Smoking Impact items is very similar to that of
generic instruments for which qualitative evaluations have
been favorable [33–35]. Whether changing the attribution
of a QOL impact survey item requires additional qualitative
evaluation is a matter of debate [36]. The latter was not
addressed in this study and this limitation should be
considered in interpreting results and addressed in future
studies because it is possible that the empirical performance
of generic and smoking-specific survey items could be
improved on the basis of smoker-specific qualitative
research.
Although the psychometric properties and performance
of TQOLITv1 measures in most tests was satisfactory,
skewness in score distributions (e.g., ceiling effects) was
substantial particularly for smoking-specific measures
among former smokers, as would be expected for relatively
young smokers who are free of smoking-related chronic
conditions [9]. One practical implication of ceiling effects is
that estimates of the QOL benefits of quitting smoking may
be attenuated. Regardless, samples of only relatively young
and otherwise well adults is a shortcoming that should be
noted. Although this focus on relatively young and well
smokers was intended, it limits the external validity
(generalizability) of findings. Future analyses also should
Table 6 Relative validity (RV) of measures in discriminating among smoking symptom groups, German and U.S current and former
smokers
Sample and measures Smoking symptom frequency F-ratio RV
Scoringa Noneb A littlec Somed
German Sample (n = 91) (n = 79) (n = 9)
Smoking Impact − 47.0 (4.4) 50.2 (5.8) 56.1 (12.3) 14.69** 1.00
SF-36 PCS + 57.4 (4.4) 56.4 (4.2) 56.7 (4.4) 1.27 0.09
SF-36 MCS + 54.4 (5.6) 54.4 (5.0) 50.0 (10.3) 2.60 0.18
US Sample (n = 177) (n = 74) (n = 8)
Smoking Impact − 47.6 (5.7) 56.4 (10.7) 61.0 (10.4) 43.26* 1.00
SF-36 PCS + 54.3 (7.7) 52.0 (6.9) 52.9 (6.7) 2.43 0.06
SF-36 MCS + 50.7 (9.5) 46.0 (11.7) 32.7 (14.7) 15.18* 0.35
*p < 0.05
aNegative (−) indicates higher score equals worse health; positive (+) indicates higher score equals better health
bTotal score less than “A little of the time” on the symptom rating scale
cTotal score between “A little of the time” and “Some of the time” on the symptom rating scale
dTotal score at or above “Some of the time” on the symptom rating scale
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examine the test-retest reliability of the Smoking Symptoms
and Smoking Impact measures, which was not possible
with the data available for this study.
Group mean scores well above the general population
average were also observed for the two generic measures
studied. In comparison with 2011 US population norms,
average scores for relatively healthy current smokers in
Germany and the US were high (close to the 70th per-
centile) for the SF-36 physical component summary and
even higher for the mental component summary. Fur-
ther study is needed to evaluate the extent to which such
high scores limit the ability of generic SF-36 measures to
detect QOL improvements in longitudinal studies. New
generic TQOLITv1 scales designed to increase the range
of reliable measurement and raise score ceilings for gen-
eric QOL measures were recently evaluated favorably
[37]. Longitudinal analyses of data quality and the stabil-
ity of repeated smoking-specific and generic measures
are underway to evaluate their usefulness in repeated-
measures outcome studies.
From the magnitude of estimates of QOL differences
observed between current and former smokers and be-
tween groups differing in the severity of smoking symp-
toms, it is likely that QOL changes from smoking to
non-smoking will be in the range typically considered an
important effect size using accepted QOL standards. For
example, the magnitude of generic QOL differences
between current and former smokers observed in these
studies is in the ballpark for minimally important differ-
ences in published comparisons from well-controlled
pharmaceutical trials [6]. They also are in the range
recommended as a standard for determining importance
by the developers of the SF-36 [38].
Conclusions
Despite the study limitations noted above, overall the
TQOLITv1 German- and English-language surveys both
enabled efficient self-administration and standardized
scoring. They have comparable and satisfactory psycho-
metric properties and sufficient empirical validity for use
in German and US studies of smoking-related QOL out-
comes for healthy smokers. New TQOLITv1 smoking-
specific measures were consistently more valid than
widely-used generic SF-36 measures across all tests for
both samples. TQOLIT warrants further testing in studies
evaluating changes in smoking behaviors which appear
likely to be associated with noteworthy QOL outcomes.
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